Adamas Pharmaceuticals (NASDAQ:ADMS) reported retrospective data from pooled Phase 3 trials of GOCOVRI in Parkinson’s disease (PD) patients.
GOCOVRI, or amantadine, was launched in late 2017 as a treatment for dyskinesias in PD patients. The retrospective analysis demonstrated that, compared with placebo, GOCOVRI reduced the number, duration, and transitions between episodes of dyskinesia and stiffness and rigidity, or OFF, periods in PD patients.
The data was published in the peer-reviewed Journal of Parkinson’s Disease. In a statement, the article’s lead author, Dr. Robert Hauser, said “This retrospective data analysis provides a window into the true patterns of these episodes throughout the day and how GOCOVRI can reduce both the number and duration of these episodes of troublesome dyskinesia and OFF, consistent with the data from GOCOVRI’s Phase 3 clinical studies.”
Added Dr. Hauser, “To my knowledge, both of these observations have not been previously reported in PD, and GOCOVRI is the first product that is clinically proven to reduce both dyskinesia and OFF, resulting in longer periods of improved movement control.”
The research article can be accessed here.
